logo-loader
Summit Therapeutics PLC

Summit Therapeutics reduces first quarter losses

For the three months ended 30 April 2019, the antibiotic developer reported an operating loss of £4.8mln, down from £6.6mln a year ago

Antibiotics
CEO Glyn Edwards said the firm was taking a leadership role in developing new classes of antibiotics to tackle resistance

Summit Therapeutics PLC (LON:SUMM) has reported a reduced loss for its first quarter and increased its cash reserves.

For the three months ended 30 April 2019, the AIM-listed firm reported an operating loss of £4.8mln, down from £6.6mln a year ago.

Revenues, meanwhile, fell to £249,000 from £3.87mln year-on-year, which the company said was related to its Sarepta licence and collaboration agreement following the group’s decision to discontinue development of its ezutromid treatment in June 2018.

READ: Summit Therapeutics soars as it hails potential of very early stage antibiotic

Summit also ended the quarter with a cash balance of £28.3mln compared to £26.9mln a year ago, adding that it had enough funds to support its operating expenses and capital expenditure until the end of January 2020.

The group’s chief executive, Glyn Edwards, said that the company was taking a leadership role in developing new classes of antibiotics which had the potential to combat the “rising threat” of antibiotic resistance.

"We believe these new class antibiotics have the potential to transform patient lives and that it is possible to show clear advantages over standard of care treatments and cost effectiveness during development. With this differentiated approach, we believe we will have the opportunity to be commercially successful”, he added.

The firm is currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which can cause diarrhoea, SMT-571 for Gonorrhoea and DDS-04 which is aiming to treat Enterobacteriaceae, a family of bacteria that includes salmonella.

In April, the company said the pre-clinical DDS-04 had successfully tackled Enterobacteriaceae in animals with urinary tract infections.

In early afternoon trading on Wednesday, Summit shares were steady at 23p.

Quick facts: Summit Therapeutics PLC

Price: £0.19

Market: AIM
Market Cap: £30.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read